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Abstract
Suppression of T cell response is thought to be involved in the pathogenesis of visceral leishmaniasis (VL). Regulatory T cell
(Treg) mediated immune-suppression is reported in animal models of Leishmania infection. However, their precise role
among human patients still requires pathologic validation. The present study is aimed at understanding the frequency
dynamics and function of Treg cells in the blood and bone marrow (BM) of VL patients. The study included 42
parasitologically confirmed patients, 17 healthy contact and 9 normal bone marrow specimens (NBM). We show i) the
selective accumulation of Treg cells at one of the disease inflicted site(s), the BM, ii) their in vitro expansion in response to LD
antigen and iii) persistence after successful chemotherapy. Results indicate that the Treg cells isolated from BM produces IL-
10 and may inhibit T cell activation in IL-10 dependent manner. Moreover, we observed significantly higher levels of IL-10
among drug unresponsive patients, suggesting their critical role in suppression of immunity among VL patients. Our results
suggest that IL-10 plays an important role in suppression of host immunity in human VL and possibly determines the
efficacy of chemotherapy.
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Introduction
Th1 effector response supposedly contains Leishmania donovani
(LD) infection while polarized Th2 like response compromises
the immune containment of LD infection, particularly at the
pathologic site(s) of VL including bone marrow (BM) [1,2].
Selective recruitment of phenotypically and functionally distinct T
cells subsets at various proportions may determine the bulk T cell
function in totality at the pathologic site(s), as in case of cutaneous
leishmaniasis (CL) [3]. Effector immune response is also critical for
efficacy of chemotherapeutic agent like SAG, as its conversion into
active tri-valent form (Sb
III) occurs within activated macrophages
[4–6]. A critical unresolved issue is the state of immune
suppression [6–8], in spite of the presence of Th1 effector immune
response (IFN-c) [9] along with IL-4 [10] and IL-10 [11]
particularly at the disease site(s) among VL patients. It is therefore
envisaged that simultaneous and persistent production of these
suppressive cytokines constitutes the key element of well observed
suppression of immune response among VL patients.
Regulatory T cells (Treg) are viewed as a major suppressor of
effector T cells (Teff) and their role in local immuno-suppression in
mice model of CL is documented [3]. Emergence of definitive
phenotypic markers of Treg cells such as FoxP3, CD39 and
CD127 enabled to study them in various infectious diseases such as
human tuberculosis [12], experimental CL [3] and advanced our
understanding of the role Treg cells play in containing these
pathogens. Accumulation of IL-10 producing Treg cells
(CD4
+CD25
+FoxP3
+) at the pathologic sites of CL has been
shown to induce parasitic persistence and reactivation of the
pathology [3]. In contrast, some studies identified FoxP3- cells as
the source of IL-10 in mice model of CL [13,14]. Similar report on
the cellular source of IL-10 among VL patients is available [15].
However, conclusive role of Treg cells in suppression of immunity
in human VL is yet to be evidenced.
Here, we show a definitive enrichment of Treg cells (CD4
+
CD25
+FoxP3
+) among VL patients, which outnumbered that of
effector T cells (CD4
+CD25
+FoxP3
2) in the BM (or disease sites)
of VL patients. We also demonstrate that the CD4
+FoxP3
+ Treg
cells isolated from the disease site (BM) of VL patients are a source
of IL-10 along with CD4
+FoxP3
2 cells. Importantly, Treg cells
persisted among the patients even after successful chemotherapy.
In addition, these cells proliferated well in response to in vitro
challenge with LD antigens, suggesting the antigen driven
expansion of Treg cells among VL patients. Interestingly, we
show that SAG responsive and unresponsive patients had
significantly lower and higher pre-treatment levels of IL-10
respectively, suggesting its role in immune-suppression in human
VL. The present investigation highlights the important role that
the Treg cells may play in the immune-pathogenesis of human VL
and determine the responsiveness to conventional anti-Leishmania
drug SAG through their suppressive influence on the local effector
T cell response.
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i) Enrichment of Treg cells in the BM of VL patients
Our data revealed significant increase of both CD4
+CD25
+ cells
(representing mixture of activated as well as FoxP3
+ Treg cells in
varying proportions; p=0.016,unpairedttest)andCD4
+CD25
+FoxP3
+
Treg cells (p=0.001, paired t test) in the BM (a major site of parasitic
invasion) of the VL patients (n=14)i nc o m p a r i s o nw i t ha u t o l o g o u s
peripheral blood (Fig. 1 A, B, C; figure S1, S2). We also observed
increase in FoxP3 mRNA in the BMMNCs of the patients to PBMCs
using RT PCR (Fig. 2 Bi & B.ii; p=0.050, Mann Whitney test).
Compared to the healthy controls (HCs), FoxP3 was more in the
Figure 1. Enrichment of Treg cells at the disease site of visceral leishmaniasis (VL) patients: A) Enumeration of FoxP3
+ Treg cells: On
gated lymphocytes, expression of CD4 and CD25 was defined and subsequently expression of FoxP3 was observed among gated CD4
+CD25
+ cells.
Overlay histogram shows FoxP3
+ cells are exclusively present among CD4
+CD25
+ T cells (thin line) and absent among CD4
+CD25
2 population (solid
line). B) Increased frequency of CD4
+CD25
+ cells at disease sites: Dual positive cells were enumerated among the MNCs isolated from the
peripheral blood, bone marrow (BM) of VL patients (n=14), peripheral blood of HCs (n=13) and normal bone marrow (NBM; n=9). CD4
+CD25
+ cells
were significantly enriched in BM-MNCs as compared to PBMCs of VL patients (p=0.016, unpaired t test). A statistically non-significant increase is also
observed in PBMCs of VL patients in comparison with that of HCs (p=0.060, Unpaired t test). Horizontal lines in dot plot depict median value.
C) Increased frequency of CD4
+CD25
+FoxP3
+ cells in BM of VL patients: Significant increase in frequency of CD4
+CD25
+FoxP3
+ cells in
PBMCs of patients (n=14) as compared to that of HCs (n=13; p=0.009, unpaired t test). CD4
+CD25
+FoxP3
+ cells are further enriched in BM-MNCs at
disease site (n=15) as compared to their autologus PBMCs (n=14; p=0.001, paired t test) and NBM (n=9; p.0.000, unpaired t test). Horizontal lines in
dot plot depict median values. Asterix values are enrichment ratios {ER=(Mean of Treg in BM- blood)/Mean of Treg in blood 6100) of FoxP3
+ Treg
cells in the NBM (ER=18.26.%) and VL patient’s BM (ER=186.93%) relative to peripheral blood. D) Increased expression of FoxP3 mRNA in
PBMCs of patients: (i) Photograph depicts increased expression of FoxP3 mRNA in PBMCs of VL patients than that of HCs. Three individual
experiments are shown herewith. (ii) Relative density analysis shows increase in FoxP3 mRNA in patient’s PBMCs (p=0.018, unpaired t test). However,
GAPDH expression remains unchanged in both the group. E) CD4
+FoxP3
+CD39
+ cells are increased in the VL-BM: Data shows higher
frequency of CD4
+FoxP3
+CD39
+ cells at the disease sites of VL patients (iv; 6.5%) as compared to NBM (iii; 0.96%). Contour plots i and ii show
fluorescence minus one (FMO) staining for iii and iv respectively. F) FoxP3
+ (Treg) and FoxP3
2 (Teff) cells within gated CD4
+CD25
+ cells: i)
Bar diagram showing significant increase in the frequency of Treg cells in the BM-MNCs (disease site) of VL patients (n=14) than that of PBMCs
(p=0.001, paired t test). However, the frequency of Teff cells at disease site (BMMNCs) is decreased as compared to peripheral compartment (PBMCs)
(Mean6SEM, p=0.023, paired t test). ii) FACS plot shows in vivo proliferating (Ki67
+; an intra nuclear cells proliferating antigen) CD4
+FoxP3
2 (Teff) cells
in blood and BM of freshly diagnosed VL patients. iii) Significant reduction in the proliferating Teff cells obtained from the disease site of VL patients
was observed (n=3; Mean6SD, p=0.049, unpaired t test).
doi:10.1371/journal.pone.0031551.g001
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Similar to the observation of Zou et al (2004) [16], we also noted
slight Treg cell enrichment in the NBM (n=9; Enrichment ratio,
ER=18.28%). However, their enrichment in the BM of VL patients
was of much higher magnitude (Fig. 1C, p.0.000, unpaired t test;
ER=186.93%), suggesting massive Treg cells enrichment in the BM
of VL patients in addition to normal default level of Treg cell
trafficking (Fig. 1C). Higher frequency of CD39
+ Treg (FoxP3
+)c e l l s
in the BM of VL patients (6.5%) compared to that of NBM (0.96%)
further substantiates our conclusion (Fig. 1E). Therefore, our data
indicates a definitive pathologic enrichment of Treg cells in the BM of
VL patients. Enrichment in the BM was observed only for Treg cells
(CD4
+CD25
+FoxP3
+;F i g .1 E ,p=0.001, paired t test), not for the
activated T cells (CD4
+CD25
+FoxP3
2). In fact, the frequency of
activated T cells was significantly lower in the BM compared to the
blood (Fig. 1E; p=0.023, paired t test). Interestingly, we noted that ex
vivo proliferation of FoxP3
2 Teffcells, as identified by Ki67 positivity,
was significantly reduced in the BM of VL patients (Fig. 1F.ii,iii & S2;
p=0.049, unpaired t test), indicating the strong suppressive influence
plausibly induced by Treg cells enri c h m e n ta tt h ep a t h o l o g i cs i t eo f
VL. Overall, our results indicate either i) host’s failure to direct the
activated effector T cells to at least one major pathologic site of VL or
ii) inhibition of host effector T cell activation by the Treg cells
recruited at the disease site.
ii) Persistence of Treg cells among VL patients
The levels of Treg cells failed to reduce significantly, particularly
in BM even after successful chemotherapy (Fig. 2A; n=15) and
parasite clearance from the BM (Table 1, figure S3). We also
observed similar trend in the level of FoxP3 mRNA in BM of VL
patients (Fig. 2B i & ii; Table 2). This was quite contrary of our
expectation as parasitic clearance fails to reduce or redistribute the
Treg cells in the local disease site of VL in human, just after
completion of therapy. It is also possible that the generation and
persistence of FoxP3
+ Treg cells may not be directly and critically
dependent on the parasite load quantitatively, rather their
presence and/or persistence may determine the susceptibility per
se to the development and/or relapse of VL. In fact, we did not
find any significant correlation between the parasitic load and the
frequency of Treg cells among VL patients (Fig. 1C, Table 1;
Correlation coefficient, r=0.193, p=0.510).
iii) Antigen induced generation of CD25
+FoxP3
+ cells
Our data revealed significant increase in the frequency of
FoxP3
+ cells after in vitro stimulation with LD antigens (whole cell
lysate, WCL) in the BM of VL patients (n=13, Fig. 3B.i, p=0.003,
paired t test). The increase in the frequency of Treg cells upon in vitro
stimulation (LD antigen specific) of BM-MNCs from VL patients
raise the possibility of in vivo antigen induced generation of Treg
cells. Our findings also show marked increase in the frequency of
CD4
+FoxP3
+ cells co-expressing Ki67 upon in vitro stimulation
with LD antigen (Fig. 3A iii–iv; figure S4). This substantiates our
conclusion that at least some fraction of enriched FoxP3
+ Treg
cells is reactive to the leishmanial antigens.
Figure 2. Persistence of Treg cells among visceral leishmaniasis
(VL) patients: A) Frequency of CD4
+ FoxP3
+ cells after
successful therapy: Scatter plot depicting no statistically significant
changes in the frequency of FoxP3
+ Treg cells after successful therapy
(post) in the BM-MNCs and PBMCs of cured VL cases as compared to its
pre-treatment levels (pre). Horizontal line in dot plot depicts median
value. B) Increased expression of FoxP3 mRNA in BMNCs of
patients and their persistence after successful therapy: (i) Gel
photograph showing increased expression of FoxP3 mRNA in BM-MNCs
as compared to autologous PBMCs. Persistence of FoxP3 mRNA after
successful therapy (post) is also shown in pictures. Individual
experiments of three patients with their follow up are shown herewith.
(ii) Relative density analysis shows increase in FoxP3 mRNA in patient’s
BMMNCs at pre (Mean6SD, p=0.050, Mann-Whitney test) and post
treatment level (Mean6SD, p=0.058, Wilcoxon sign rank test). However,
GAPDH remain unchanged in all three categories.
doi:10.1371/journal.pone.0031551.g002
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CD4
+FoxP3
+ Treg cells derived from BM could produce IL-10,
whereas, IL-10 production by the CD4
+FoxP3
2 T cells was also
observed (Fig. 4A & figure S6). Our results suggest that the Treg
cell of VL patients, particularly from the BM, responded to LD
antigen with production of immuno-suppressive cytokine IL-10
(Fig. 4B). Further, we intended to identify the cellular source(s) of
IL-10 among VL patients. MNCs derived from the blood and BM
of VL patients secreted IL-10 following in vitro PHA and antigen
stimulation (Fig. 4C). However, the same did not show or showed
low levels of IL-10 in PBMCs and BMMNCs respectively, when
FoxP3 enriched CD25
+ cells were depleted by magnetic sorting (as
confirmed by FACS based staining for FoxP3 of an aliquot of
unsorted MNCs; Fig. 4C i & ii). BM derived MNCs showed
spontaneous release of detectable levels of IL-10 in vitro (without
stimulation), suggesting its presence in higher magnitude in local
disease site (Fig. 4C ii). However, Treg enriched CD25
+ cells may
not be the sole source of IL-10 as some levels of IL-10 could still be
detected even after depletion of Treg cells (CD25
+) from the BM
MNCs (Fig. 4C.ii). Thus, we conclude that Treg cells are one
important source of IL-10 production, particularly in the BM of
VL patients and plausibly play critical role in mediating immune-
suppression among VL patients.
Blocking of IL-10 along with polyclonal stimulation (Fig. 4D)
caused significant increase in the frequency of activated (CD69
+)
CD4 T (CD3
+CD8
2) cells as compared to polyclonal/antigenic
stimulation alone, respectively. Having shown previously that,
among VL patients IL-10 is also produced by the Treg cells, we
intended to see the effect of Treg cells depletion on the T cell
activation. Frequency of CD69
+ CD4 T (CD3
+CD8
2CD69
+) cells
were increased among CD25 depleted BMMNCs upon polyclonal
stimulation (Fig. 4D.iv & v; p=0.009, paired t test). Concentrations
of soluble IL-10 were also measured in these experiments (figure
S7). With antigen stimulation BMMNCs of VL patients showed
significant increase of CD69 expression under both conditions (IL-
10 blocking and CD25- depleted cells) as compared to antigen
stimulation alone (Fig. 4E; p=0.065, unpaired t test & p=0.025,
paired t test respectively). This indicates immuno-suppressive effect
of IL-10 {and its source CD25
+ (FoxP3
+) cells} on the antigen
specific activation of CD4 T cells. Blocking of IL-10 also increases
IFN-c production upon polyclonal stimulation (figure S8).
Table 2. Comparative densitometric analysis of the band intensity of FoxP3 mRNA.
Average intensity
Set-I Healthy PBMCs Patients PBMCs
GAPDH 6.43 5.76
FoxP3 0.86 2.133
**Ratio (r) 0.135 0.369
Relative ratio 1 2.7
Set-II Patients PBMCs
Patients BMMNCs
Pre treatment
Patients BMMNCs
Post treatment
GAPDH 4.40 4.30 4.66
FoxP3 0.73 1.63 2.13
**Ratio (r) 0.166 0.379 0.457
Relative ratio 1 2.28 2.75
Ratio of relative intensity shows 2.7 times increase in band intensity of FoxP3 mRNA in patient PBMCs as compared to healthy PBMCs. FoxP3 band intensity is 2.28 times
higher among patient’s BMMNCs compared to their PBMCs. In cured cases, band intensity is 2.75 times higher than its pre-treatment level. Set I experiments were
executed with higher amount of DNA compared to set II, due to extremely lower expression of FoxP3 in healthy subjects. (*Between Patient’s PBMCs and BMMNCs at
pretreatment level, # Between Patient’s BMMNCs at post treatment level, ** r=average intensity of FoxP3 bands/GAPDH bands).
doi:10.1371/journal.pone.0031551.t002
Table 1. Details of visceral leishmaniasis patients monitored
in the study.
No. of patients 42
Demographic characteristics
Age (Mean 6 SD, range) 24.80616.26 (3–70)
Sex (M/F) 25/17
Ethnicity Indian
Region Bihar, India
Basis of diagnosis
Screening (rK39) No. of cases
Positive 31
Negative 03
Not tested 08
Confirmatory (Parasite demonstrations
in bone marrow smear, parasite load),
pre-therapy
No. of cases
+12 1
+21 4
+36
+61
Parasite load, post therapy Not detectable (in all cases)
Other diagnosis
WBC count (Mean 6 SD, range) 3087.561141.8 (1700–5400)
Hb (Mean 6 SD, range) 6.8161.75 (4.3–10.4)
Platelet count (Mean 6 SD, range) 97.75642.88 (21–173)
doi:10.1371/journal.pone.0031551.t001
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We measured levels of pro-inflammatory (IFN-c) and suppresso-
genic cytokines (IL-10, IL-4) in serum and BMA (bone marrow
aspirate) of VL patients. Our findings demonstrate high levels of IL-
10 (Fig. 5D, E.i & E.ii) and IL-4 (Fig. 5A) in serum and BMA of VL
patients beforetreatment. Contrary to ourexpectation,we observed
the persistence of IL-10 in the serum as well as BMA, at least in half
of the patients. Interestingly, higher level of IL-4 completely went
below the detectable levels after successful therapy. This is
suggestive of the fact that IL-4 is more related to the pathologic
status of the patients as a signature cytokine, while IL-10 may be
more important for immunoregulatory function. Levels of IFN-c
were found to persist even after chemotherapy in the BMA of VL
patients, even though its levels declined with treatment (Fig. 5B)
indicating that as an effector cytokine, its presence in treatment
naı ¨ve patients failed to confer protection possibly due to higher pre-
therapeutic levels of IL-4 (and IL-10). Thus, decline in the levels of
IL-4 may be associated the restoration of immune response
necessary for disease containment.
Figure 3. L. donovani antigen driven induction of FoxP3
+ cells in BM-MNCs of visceral leishmaniasis (VL) patients: A i–ii)
Representative plot shows increased frequency of FoxP3
+ cells (%) in MNCs upon in vitro stimulation with LD antigen (whole cell lysate, WCL). A iii–
iv) Representative plot shows increase in the positivity of Ki67 (an intra nuclear cells proliferating antigen) among gated CD4
+FoxP3
+ cells upon
antigen stimulation (30.8%) as compared to unstimulated cells (16.9%). Bi ) Scatter plot representing the frequency of Foxp3
+ Treg cells in gated
CD4
+ cells BM-MNCs (n=13) of VL patients upon in vitro stimulation with LD antigen. Significant increase in the frequency of FoxP3
+ Treg cells from
BM-MNCs of VL patients occur upon antigen stimulation (p=0.003, paired t test). Horizontal line in dot plot depicts median value. Bi i ) Plot shows
increase in the frequency of FoxP3
+ cells in BMMNCs of VL patients upon stimulation (% increase=(frequency of Treg cell in stimulated culture-
unstimulated culture)/frequency of Treg in unstimulated6100).
doi:10.1371/journal.pone.0031551.g003
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among VL patients
Therapeutic response of SAG, a pro-drug requiring its
conversion in to active component within activated macrophages,
is believed to critically depend on the Th1 effector immune
response [4,5]. We therefore, intended to see if therapeutic
response to conventional anti-Leishmania drug, SAG is associated
with the levels of immune-suppressive cytokine IL-10 or vice versa.
We measured the levels of soluble IL-10 among untreated VL
patients (serum and BMA) and correlated with the clinical
Figure 4. IL-10 production by the Treg cells derived from visceral leishmaniasis (VL) patients: A) IL-10 producing FoxP3
+ cells in
BMMNCs of VLs patients before treatment: (i) Histogram plot depicts gating strategy of CD4
+ cells. Bi-variant plots show IL-10 production by
CD4
+FoxP3
+ Treg cells and CD4
+FoxP3
2 cells under different in vitro conditions (ii) without stimulation and (iii) with L. donovani antigen stimulation.
B) IL-10 production by CD4
+FoxP3
+ and CD4
+FoxP3
2 cells: Scatter dot plot shows frequency of IL-10 producing cells within gated
CD4
+FoxP3
+ (Treg) and CD4
+FoxP3
2 (Teff) cells in blood as well as in BM of VL patients before anti-Leishmania therapy. Data shows that FoxP3
+ cells
are one of the important producers of IL-10 along with CD4
+FoxP3
2 cells. Horizontal lines in dot plot depict median value. Significant differences are
indicated with p-values using paired t test. C) CD4
+CD25
+ (FoxP3 enriched) cells are major producer of IL-10 at disease site (BMA): CD25
+
cells were magnetically sorted out from (i) PBMCs and (ii) BMMNCs. IL-10 was measured in supernatant of cultured cells (unsorted cells and CD25
depleted cells) stimulated with PHA (mitogen) and L. donovani antigen. IL-10 production was dominantly restricted to CD25
+ cells which were
enriched with Treg cells. Data are represented in Mean6 SD. Significant differences are indicated with p-values using paired t test. D) Effect of IL-10
blocking and depletion of FoxP3
+ enriched cells on T cell activation upon polyclonal stimulation: i–v) In vitro PMA stimulation for 24 hrs
caused activation of CD4 T cells (CD3
+CD8
2) derived from BM-MNCs as measured by the expression of CD69 (% positive cells) on them (v; p=0.011,
paired t test). Significant increase in the frequency of CD69
+ early activated CD4 (CD3
+CD8
2) T cells occurred upon PMA stimulation of BM-MNCs for
24 hrs when endogenously produced IL-10 was blocked by monoclonal antibody (v; p=0.018, paired t test). Similar increase in the frequency of
CD69
+ CD4 (CD3
+CD8
2) T cells was also observed when CD4
+CD25
+ (Treg enriched) were sorted out using MACS sorting kit and CD25
2 BMMNCs
were cultured with PMA for 24 hrs (v; p=0.009, paired t test). Data are represented in Mean6 SD. E) Treg cells and IL-10 suppress L.donovani
specific activation of CD4
+ T cells derived from pathologic site: LD antigen caused significant increase in the frequency of CD69
+CD4
+ T cells
(p=0.036, paired t test) after 72 hrs of stimulation. Upon blocking of soluble IL-10 by anti IL-10 ab, the frequency of CD69
+CD4
+ T cells were increased
as compared to antigen alone (p=0.065, unpaired t test). Upon stimulation of CD25 depleted BMMNCs with antigen for 72 hrs, the frequency of
CD69
+CD4
+ T cells was increased as compared to antigen stimulated unsorted cells (p=0.025, paired t test) as well as unstimulated CD25 depleted
cells (p=0.014, paired t test). However, in 24 hrs stimulation experiments, unsorted (with/without blocking of IL-10) and CD25 depleted BMMNCs
upon stimulation with LD antigen show no significant increase in the frequency of CD69
+CD4
+ T cells. {A=unsorted cells (with/without ag
stimulation), B=CD25 depleted cells (with/without ag stimulation), C=unsorted cells with IL-10 blocking}. Data are represented in Mean6 SD.
doi:10.1371/journal.pone.0031551.g004
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subjected freshly recruited patients to SAG and followed their
therapeutic response till the completion of therapy (SAG
responsive, n=6; SAG unresponsive cases, n=9). It was interesting
to observe a tight inverse correlation between the therapeutic
response to SAG and the levels of IL-10 in the serum as well as
BMA of VL patients. Taken together, our results demonstrate that
SAG failed to cure the cases with higher levels of IL-10, while
patients with relatively lower levels of IL-10 responded effectively
to SAG with clinical and parasitological cure (Fig. 5E.i).
Discussion
Recent identification of Treg cells and their dominant
suppressive influence on the effector T cell function suggests their
critical involvement in VL. Mendez et al. [3] demonstrated that
Treg cells predominantly produced IL-10 and mediated the
suppression of immune response observed among mice with CL.
In an elegant animal study, Suffi et al. [17] showed a definitive role
of Treg cells in causing suppression of local effector immune
response by altered ratio of Treg and effector T cells and
production of IL-10 at the pathologic site. However, the precise
cellular origins of IL-10 among VL patients are yet to be
deciphered convincingly. Moreover, studies on the Treg cells and
their role in suppression of effector T cells response among human
VL patients are scanty. Therefore, we attempted to understand the
status of Treg cells in terms of their frequency, function and
enrichment among VL patients, particularly at the pathologic
site(s).
Here, we demonstrate definitive enrichment of Treg cells
among VL patients, particularly at major pathologic site (BM).
Previously Zou et al reported default Treg cell enrichment in
normal bone marrow (NBM) [16]. However, in our study the Treg
cell enrichment among VL patients was of profoundly higher
magnitude (Fig. 1C), we also noted dominant expression of CCR4
on the robustly enriched Treg cells among VL patients (figure S5).
These findings indicate that i) in addition to the normal default
enrichment (ER=18.28%), a massive accumulation of Treg cells
Figure 5. Dominance of soluble suppressive cytokine(s) at disease site (bone marrow, BM) of visceral leishmaniasis (VL) patients: A)
High Levels of IL-4 in BM among VL patients: Scatter plot shows increased level of IL-4 in serum of VL patients (n=11) than that of HCs (n=10;
p=0.0005, Unpaired t test). Its level was further increased in BMA of VL patients (n=9; p=0.0005, Paired t test). After successful therapy (post), the IL-4
declined to undetectable levels in serum (n=8) and BMA (n=9) of cured VL cases. B) Elevated levels of IFN-c among VL patients: Scatter plot
depicting higher levels of IFN-c (pg/ml) in the serum of untreated VL patients (n=21) than that of HCs (n=17; p=0.064, unpaired t test). Level of IFN-c
is further increased in BMA (n=19) as compared to that of autologous serum (n=21, p=0.001, Paired t test). After successful therapy (post), levels of
serum IFN-c is reduced in cured cases (n=8) below their level at 0 day (pre). However, its level in BMA of cured cases (n=9) remained high even after
therapy, even though reduced to some extent after successful treatment (p=0.043, Paired t test). C) Ratio of IL-4 and IFN-c shows dominance of IL-4
over IFN-c in serum as well as BMA before therapy. Post therapy, IFN-c dominates over IL-4 quantitatively. D) High levels of IL-10 in untreated
patients and its persistence after successful therapy with AmB: Increased levels of IL-10 was observed in the serum as well as BMA of
untreated VL patients (n=12) as compared to serum of HCs (n=14; p=0.0005, Unpaired t test). After therapy with AmB, IL-10 levels are maintained at
high level in BMA (n=12). E) IL-10 in SAG responsive and unresponsive patients: Pre treatment levels of IL-10 in the serum and BMA of VL
patients could segregate SAG unresponsive patients from the responsive group. IL-10 levels were significantly higher in serum (p=0.004, Mann
Whitney test) and BMA (p=0.007, Mann Whitney test) of patients who did not respond to SAG therapy. Horizontal line in dot plot depicts median
value.
doi:10.1371/journal.pone.0031551.g005
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plausibly induced by the disease pathology and/parasite burden
and iii) their selective recruitment by CCR4 and its ligands.
Interestingly, the enriched Treg cells of the BM of VL patients
showed evidence for spontaneous ex vivo (figure S9) and in vitro
antigen induced (Fig. 3) proliferation (Ki67 positivity) suggesting
their antigen specificity and induction at the pathologic site (BM).
We therefore conclude that antigen dependent expansion of
Treg cells at the disease milieu contribute to robust Treg cell
enrichment observed among VL patients. However, their
chemokine receptor driven (CCR4) selective recruitment can not
be ruled out and may work synergistically. This is further
supported by recent report on generation of suppressive T cells
in presence of excess antigenic load [17,18]. Therefore, enriched
Treg cells plausibly suppress effector T cell response to create a
state of local immune deficit in human VL. This is confirmed by
higher proliferation of peripheral Teff cells relative to the same
derived from BM of patients (Fig. 1F ii & iii). Therefore, we
conclude that Treg cells play a definitive role in the local
suppression of effector T cells. Recent studies [15,19], using
mRNA and FACS based estimation of FoxP3 from the splenic
aspirate, did not note Treg cell enrichment at the local disease site
of VL patients. In contrast, here we show significant enrichment of
CD4
+CD25
+FoxP3
+ (CD39
+) Treg cells by both mRNA (Fig. 2B)
as well as protein level expression (by FACS based staining of the
Treg cells with CD4, CD25, FoxP3 and CD39; Fig. 1C & E) in the
BM of the patients with VL. The discrepancy between the findings
of the present study and that of Nylen et al [15] may be due to the
differences in the local disease sites (spleen and BM) and/or the
dynamics of Treg cell enrichment in organ specific manner.
Previous studies on animal models of protozoan infections
including CL [13,14] and among VL patients [15] demonstrated
higher levels of IL-10 and identified FoxP3- T cells as its source.
However, we observed that the CD4
+FoxP3
+ Treg cells produced
IL-10 in an antigen dependent manner along with CD4
+FoxP3-
cells (Fig. 4A & B). Reduction in the IL-10 production after
depletion of CD25
+ (FoxP3
+ enriched) cells substantiates our
conclusion that FoxP3+ Treg cells are important source of IL-10
among VL patients (Fig. 4C). Moreover, increase in the frequency
of LD specific CD69
+ activated T cells upon blocking IL-10 in our
hands strongly suggests IL-10 mediated suppression of T cell
activation among VL patients (Fig. 4E) Taken together, here we
provide convincing evidences for i) antigen induced expansion and
enrichment Treg cells in at the pathologic site (BM), ii) cellular
source (FoxP3
+ Treg and FoxP3- non-Treg cells) of IL-10 and iii)
IL-10 mediated suppression of LD specific effector T cell response
in human VL. Thus, inhibiting the recruitment, expansion and/or
the function (particularly IL-10 production) of Treg cells may
constitute a major approach for restoration of the local effector
immune response among VL patients.
Considering the suppressive role of Treg cells and IL-10,
successful chemotherapy is envisaged to reverse the suppressed
state of immunity. Contrary to our expectation and existing
literature [15,19], persistence of Treg cells (Fig. 2A) and IL-10
(Fig. 5D) were observed even after the successful chemotherapeutic
among half of the cured VL cases. Study of Murray et al [20] on
achieving sterile cure with blocking IL-10 pathway in mouse VL
model relates to the findings of our study. Persistent presence of
Treg cells and their selective recruitment at the disease site(s) may
play critical role in persistence of residual parasite burden even
after clinically effective chemotherapy, which may result in the
relapse of the disease, development of PKDL [21] and/or
susceptibility to re-infection. Our results provide mechanistic
insight in to its mechanism parasite persistence. Interestingly, the
levels of Th2 associated cytokine IL-4 decreased to the
undetectable level (along with elevated levels of IFN-c) following
chemotherapy (Fig. 5A, B). Taken together, this suggests that
subsequent to effective chemotherapy, a fine balance ensues
between the protective cytokine IFN-c and immuno-suppressive
cytokine IL-10 (plausibly derived from the persisting Treg cells)
and tilting its balance towards the later at any subsequent point of
time may cause disease relapse [9]. Delineating the factors
triggering such events is important for understanding the
immunopathology of relapse of VL and occurrence of PKDL in
human.
Chemotherapy of VL with first line of relatively inexpensive
drug, SAG has suffered a major setback due to development of
unresponsiveness [22,23]. This has compounded the VL elimina-
tion program among impoverished population inflicted with this
disease in India and adjoining region [22]. SAG is a pentavalent
antimonial pro-drug requiring its conversion in the host into its
active trivalent form [4,24]. Conversion of SAG primarily occurs
by reactive oxygen species (ROI) following Th1 response (IFN-c)
dependent activation of macrophages [4,24]. Thus, synergistic and
complementary function of the chemotherapy and the protective
immunity constitute the drug immune interphase and believed to
determine the efficacy of SAG. We hypothesized that IL-10
mediated suppression of immunity plausibly dictate the response to
SAG therapy among VL patients. We noted a tight and inverse
correlation between the levels of IL-10 and response to SAG
therapy (Fig. 5E). We propose that elevated levels of IL-10 released
primarily from the enriched Treg cells shift the dynamics of drug
immune interphase towards immune-suppression, thus preventing
the induction of proinflammatory cytokines (IFN-c), macrophage
activation and lead to SAG unresponsiveness. Reversing the Treg
cell recruitment and inhibiting their IL-10 production or blocking
the IL-10 at the pathologic site(s) may constitute an effective
intervention modality for repairing the immune deficit of VL
patients and thereby contain the infection as well as improve the
drug (SAG) response. Moreover, levels of IL-10 and Treg cells in
the BM may prove to be a potent bio-marker of the disease
severity and drug response of VL patients.
Materials and Methods
1) Healthy subjects and patients
The study included 42 parasitologically confirmed patients
[mean age 24.80616.26 yrs; range 3–70 yrs; 25 males and 17
females). These patients attended Balaji Utthan Sansthan (BUS),
Patna, Bihar, India for diagnosis and treatment. Quantification of
parasite before and after therapy was performed in the BM of the
recruited patients [25]. Seventeen HCs {Healthy family members
and non family members (living in the same endemic region)},
chosen from among the persons attending patients, were also
included in the study. All subjects were HIV negative. None of the
patients was on anti-Leishmania treatment at the time of enrolment
in the study. Normal bone marrow (NBM) specimens were
obtained from attendees at our haematology clinic for diagnosis of
presumptive hematologic disorders (such as idiopathic thrombo-
cytopenic purpura (ITP), hypersplenomegaly, anaemia etc.) Their
bone marrow aspiration was performed as a part of routine
diagnostic evaluation. We recruited 11 such cases with patient’s
informed consent. Subsequently, 9 cases were confirmed normal
clinically as well as haematologically and recruited in the study.
Samples (Blood, BM and serum) from these patients were
collected in heparinized tubes (BD Vacutainer
TM sodium heparin,
Cat. No. 366480, Becton Dickinson, Franklin Lakes, NJ) and
transported to All India Institute of Medical Sciences (AIIMS),
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(demonstration of parasite) (Table 1). Patients were kept on
continuous monitoring in hospitals.
2) Therapy
Recruited patients were treated with SAG (20 mg/kg body
weight for 28 days) and AmphotericinB (AmB; 1 mg/kg body
weight for 20 days) as per WHO guidelines. Treatment was
stopped for patients who did not respond to SAG and/or
developed cardiac illness and after interval of 1 or 2 days patients
were instituted on therapy with a second line of drug like AmB.
3) Ethics Statement
The research project was approved by the Institutional Ethics
Committee of AIIMS, New Delhi (Ref. No. B-11/6.10.2006;
October 17, 2006) and BUS, Patna, Bihar. Written informed
consent was obtained from all study participants including healthy
subjects. For minor children and for patients those who cannot
read and write, written informed consent was provided by their
legal guardian.
4) Reagents
RPMI medium (Roswell Park Memorial Institute; Caisson
Laboratories Inc., Cat: 010P, with L-glutamine, without HEPES
and NaHCO3) supplemented with L-glutamine (G-5763, Sigma
Chemicals Co., St. Louis, USA), antibiotics (Pen-Strep-Ampho
Sol; Biological Industries, Kibbutz Beit Haemek, Israel) and fetal
calf serum (10%, Biological Industries, Kibbutz Beit Haemek,
Israel) were used for cell culture experiments. Permeablization
of cells for intracellular antigen detection was done with 0.3%
Saponin (S-7900, Sigma Chemicals Co., St. Louis, USA).
Monoclonal antibodies used were FITC conjugated CD3, CD4,
CD39, IFN-c (BD Pharmingen, San Diego, CA, USA); PE
conjugated CD3, CD25, CD69, Ki67 set (all BD pharmingen, San
Diego, CA, USA); PerCP/Cy5PE conjugated CD4, CD8 (all BD
Pharmingen, San Diego, CA, USA); APC conjugated CD3, CD4
(all BD Pharmingen, San Diego, CA, USA). FoxP3 staining kits
were purchased from e-Biosciences (Cat. No. 71-5776-40, e-
Biosciences, San Diego, CA, USA). a-CD25 microbead antibodies
along with column (MACS
R MS separation column) and magnetic
sorting apparatus were purchased from Miltenyi Biotec.
5) Isolation of MNCs from blood and BMA
Briefly, mononuclear cells (MNCs) were isolated from heparin-
ized blood and BMA by Ficoll Hypaque gradient centrifugation,
washed thrice with incomplete RPMI (without FCS) and finally
suspended in complete RPMI-1640 supplemented with 10% FCS
(Caisson Laboratories, Logan, UT). The viability of cells was
checked by trypan blue dye exclusion test and was more than 98%
[12]. Before the density gradient centrifugation, the BMA was
centrifuged at 2000 rpm for 5 mins in micro-centrifuge. The pellet
containing cells will be separated from the liquid part, which will
be used for the detection of soluble cytokine(s) in BMA.
6) Surface and intracellular staining and in vitro culture of
cells
Briefly, isolated cells were incubated directly with fluorescence
labeled monoclonal antibodies in staining buffer (PBS+BSA+azide)
for 15 min on ice. After washing, fixation and re-washing, cells
were transferred in FACS tube (BD FALCON) for data acquisition
by three/four-color flow cytometer (Beckton Dickinson, FACS
calibur). For the staining of intra-cytoplasmic antigens (e.g. IL-10,
Ki67 etc), cells were permeabilized by using permeabilization
buffer (0.3% saponin) after fixation for 30 mins at room
temperature [12].
Cells were cultured (2610
6cells/ml) in microtitre plate (96 well
and U bottom plates, BD Falcon) in presence of PHA (5 ng/ml,
Sigma-aldrich co, St. Louis, USA) for 72 hours at 5% CO2 at
37uC. For antigen stimulation study, cells were incubated with LD
antigen (whole cell lysate; 10 mg/ml) with purified a-CD28 and a-
CD49d antibody (AbD Sertec, Oxford, UK, LE/AF, Cat.
No. MCA70EL & MCA923EL respectively) for 24 hrs and
monensin (Golgi transport inhibitor; 1 mM, Sigma-aldrich co, St.
Louis, USA) was added in last 6 hrs (20). For Blocking studies,
unconjugated anti-IL-10 monoclonal antibody (NA/LE, BD
Pharmingen, San diego, CA, USA) was mixed with MNCs (2
million/ml) prior to the addition of PHA [12].
7) Staining of cells for FoxP3 antigen
Briefly, 1–2610
6 MNCs were first, surface stained (e.g. CD4,
CD25, CD39 and CCR4 etc) and were stained for FoxP3 antigen
using FoxP3 staining (FITC/PE) kit (Cat. No. 00-5123-43,
ebiosciences, San diego, CA, USA). To assure specificity of
CD4, CD25 & FoxP3 staining, we performed fluorescence minus
one (FMO) and isotype staining (figure S1) of the same specimens
[12]. To evaluate the proliferation of Treg and Teff cells, cells
were stained with anti-Ki67 and anti-FoxP3 abs following in vitro
stimulation with LD antigens using FoxP3 staining protocol (figure
S4). To enumerate the IL-10 producing FoxP3
+ cells (figure S6),
antigen stimulated cells were stained for IL-10 and FoxP3 using
the same protocol. To confirm the staining specificity, we
performed fluorescence minus one (FMO) for IL-10 (figure S6).
For enumeration of FoxP3
+ Treg cells, 2–5610
6 events (depending
on cell yield) were acquired to obtain analyzable number of
FoxP3
+ cells.
8) Amplification of FoxP3 mRNA
Total mRNA was extracted from the MNCs obtained from
peripheral blood and local disease site specimen, using Trizol
reagent (Sigma-Aldrich Inc., St. Louis, USA) as recommended by
the manufacturer. mRNA was converted into cDNA by Reverse
Transcriptase -PCR. Quality was assessed using ND-1000
spectrophotometer (NanoDrop Technologies, USA). Isolated,
precipitated & quantified cDNA was then utilized for the
amplification of Foxp3. GAPDH (housekeeping gene) was used
as a positive control. All constituents of the PCR mix except the
individual cDNA samples were mixed together and mixed
thoroughly. 21 ml of the reaction mix was dispensed into PCR
tubes and 0.5–1 mg( 5ml) individual cDNA was added to each
tube. Sterile distilled H2O and standard cDNA were used as
negative and positive controls, respectively. The tubes were spun
down briefly for 10–15 seconds and placed on the heat block of
thermal cycler. The amplification was accomplished on a DNA
thermal cycler (GeneAmp PCR System 9700, Applied Biosystems,
USA) at successive incubation steps at three different temperatures
as follows. Initial incubation at 94uC - 5 min followed by 94uC–
1 min (denaturation), 57.7uC -1 min (annealing), 72uC – 1.5 min
(amplification) for 35 cycles.
Following sets of primers were used:
FoxP3 F 59 TGC CTC CTC TTC TTC CTT GA 39
R5 9 CCA CTT GCA GAC ACC ATT TG 39
GAPDH F 59 AAA ATC AAG TGG GGC GAT GC 39
R5 9 TGA GCT TGA CAA AGT GGT CG 39
1.5% agarose gel was used to analyze PCR bands. A molecular
weight DNA marker (Bangalore GENEI, India) having uniform
banding pattern of 100 bp to 1000 bp was loaded in the lateral
well. DNA bands of 439 bp were identified relative to the markers
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tion system (Syngene, Cambridge, UK) [12].
9) ELISA for IL-10, IL-4 and IFN-c
Sandwich ELISA for soluble cytokines (IL-4: Cat. No. 555142;
IL-10: Cat. No. 555157 & IFN-c: Cat. No. 555142; BD
Pharmingen, San diego, CA, USA) and chemokines (MDC: Cat.
No. DMDOO & TARC: Cat. No. DDNOO; Quantikine immu-
noassay, R&D system, Minneapdis, MN, USA) were performed in
serum and BMA of patients. After development of color, stop
solutions were added to stop the reaction and O.D. was taken at
590 nm in a 96 well plate ELISA reader (Anthos 2020; Anthos
Labtec Instruments).
10) Culture of parasite Leishmania donovani
Clinical isolate of promastigotes (from Balaji Utthan Sansthan,
Bihar) were maintained in modified DMEM supplemented with
10% FCS, adenosine, hemin, biotin and triethanolamine etc., at
25uC in BOD incubator. These were maintained in the laboratory
by frequent passaging of cells, until the colour of the medium
became yellowish and/or cells became confluent.
11) Preparation of antigen of L. donovani
Parasites from log phase growth were collected by centrifugation
(6500 g) for 10 min at 4uC. Pellet of LD was washed twice by PBS
and resuspended in sterile PBS and was sonicated in BRANSON
250 sonicator, using 50% duty cycle (i.e. 30 seconds on,
30 seconds off) for 15 mins at 4uC. Sonicate was mixed and the
protein concentration was assessed with a ND-1000 spectropho-
tometer (NanoDrop Technologies, USA). 10 mg of protein was
used to stimulate 1–2 million of cells in one ml [26].
12) Statistical analysis
The normal continuous variables are presented in mean and
with standard deviation. However, non-normal co-variants are
shown in the median and interquartile range. For the comparison
of all continuous variables between the studied group, paired t-
test/Wilcoxon Sign rank test (normal/non-normal) and unpaired t
test/Mann Whitney test (normal/non-normal) are used. P-value
less than 5% level of significance will regarded as significant
results. Horizontal line in the scatter plot represents the median
value and bar diagram shows mean6SD of data set. The analysis
is done using SPSS 15.0. Graphs and figures were made in
GraphPad Prism 5 version.
Supporting Information
Figure S1 FACS contour plot showing gating strategy for
CD4
+CD25
+FoxP3
+ Treg cells. i) Bi-variant contour plot
showing co-expression of CD25 and FoxP3 on gated CD4
+ T cells
in BMMNCs of VL patients. ii) Representative FACS contour
plot depicting the gating strategy to enumerate CD4
+CD25
+
FoxP3
+ Treg cells among VL patients. 2–5610
6 events were
acquired to achieve sufficiently sizable number of FoxP3
+ for
further analysis. Gating of positive (vs negative) cells was based on
either isotype and/or fluorescence minus one (FMO) staining.
Upper panel shows plots demonstrating isotype control for CD25
staining respectively. FoxP3
+ cells were enumerated on gated
CD4
+CD25
+ cells using isotype control for FoxP3 staining (lower
panel).
(DOC)
Figure S2 Level of FoxP3 in CD4+CD25- cells from
visceral leishmaniasis (VL) patients: Bar diagram shows
frequency of FoxP3
+ cells among CD4
+CD25
+ and CD4
+CD25
2
cells from blood and bone marrow (BM) of VL patients (n=14).
(DOC)
Figure S3 Clearance of parasite from BM after comple-
tion of therapy: Representative image photographs of Giemsa
stained BM smear slides of VL patients (n=5) showing presence
and disappearance of LD in the BM of VL patients before and
after anti-Leishmania therapy respectively. Inset shows magnified
view of LD bodies.
(DOC)
Figure S4 Staining of Ki67
+ proliferating CD4 cells: For
in vitro antigen induced or in vivo proliferation assay of Treg cells,
mononuclear cells were stained for Ki67 (an intra-nuclear cell
proliferating antigen) and FoxP3 using FoxP3 staining protocol.
To confirm our staining, isotype staining was also performed for
Ki67. Contour plots show isotype and Ki67 staining of gated
CD4
+FoxP3
2 cells derived from PBMCs of VL patients.
(DOC)
Figure S5 Higher frequency of CCR4
+ Treg cells
(FoxP3
+) in BM of VL patient as opposed to NBM: i)O n
gated CD4
+ T cells, co-expression of CCR4 and FoxP3 was
observed. ii) Expression of CCR4 was observed on gated
CD4
+FoxP3
+ and CD4
+FoxP3
2 cells. Overlay histogram shows
increased frequency of CCR4
+ cells among gated Treg population
(thin line) as compared to CD4
+FoxP3
2 population (solid line) of
BMMNCs of VL patients. iii) Overlay histogram shows increased
frequency of CCR4
+ cells among gated Treg population (thin line)
as compared to CD4
+FoxP3
2 population (solid line) of normal
BMMNCs. iv) Scatter plot shows increased number of CCR4
+
Treg cells among VL patients.
(DOC)
Figure S6 Treg cells are one of the producers of IL-10 in
visceral leishmaniasis (VL) patients: (i–iii) FACS contour
plots show co-expression of FoxP3 and IL-10 PBMCs of healthy
subject upon (iii) polyclonal stimulation as compared to (i)
unstimulated. (ii) Gating is based on the fluorescence minus one
(FMO) staining for IL-10. (iv–v) FACS dot plot shows IL-10
production by FoxP3
+ and FoxP3
2 cells among CD4 T cells
derived from blood of VL patients under different in vitro
conditions (iv) no stimulation and (v) L. donovani antigen
stimulation. (vi–vii) Data shows that FoxP3
+ cells from bone
marrow (BM) are one of the important producers of IL-10 along
with CD4
+FoxP3
2 cells upon in vitro stimulation with L. donovani
antigen.
(DOC)
Figure S7 Activation of T cells is repealed upon sorting
out CD25+ cells and IL-10 blocking: (A) Expression of CD69
is measured to estimate activation of T cells. Upon mitogenic
stimulation (PHA), cells from bone marrow of VL patients are
significantly expressing CD69, which is further increased if CD25
depleted cells are stimulated with PHA. The similar effect is
observed when soluble IL-10 is blocked with anti-IL-10 monoclo-
nal ab. (B) Culture supernatant from experiment-A was stored and
estimated for soluble IL-10. Finding suggests that IL-10 was
significantly decreased upon sorting out CD25+ cells, indicating
that the one of the cellular source of IL-10 is CD25+ cells.
(DOC)
Figure S8 Immuno-regulatory IL-10 suppresses the
IFN-c production upon polyclonal stimulation: i–iv)
In vitro PMA stimulation of BM-MNCs from VL patients (n=5)
caused drastic production of IFN-c by CD8
+T cells (iv; p=0.029,
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CD8
+T cells upon PMA stimulation of BM-MNCs for 24 hrs
when endogenously produced IL-10 was blocked by monoclonal
antibody (iii & iv; p=0.032, unpaired t test).
(DOC)
Figure S9 Proliferation of non-Treg cells are inversely
correlated with the frequency of FoxP3
+ Treg cells in
bone marrow (BM) of VL patients: Data shows analysis of
proliferating Treg (Ki67
+FoxP3
+) and non-Treg (Ki67
+FoxP3
2)
cells from (i&i i ) blood and (iii & iv) BM of VL patients. Findings
show decreased proliferation of CD4+FoxP3- cells at the disease
sites (BM) compared to blood and sign of spontaneous prolifer-
ation of FoxP3
+ Treg cells Gating is based on the isotype staining
for Ki67 (i & iii).
(DOC)
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